A multicenter phase II study of docetaxel 60 mg/m 2 as first-line chemotherapy in patients with advanced or recurrent breast cancer

被引：6

作者：

Ishikawa T. ^{[1
]}

Shimizu S. ^{[2
]}

Inaba M. ^{[3
]}

Asaga T. ^{[3
]}

Katayama K. ^{[4
]}

Fukuda M. ^{[5
]}

Tokuda Y. ^{[6
]}

Ishida K. ^{[7
]}

Fukuma E. ^{[8
]}

Suda T. ^{[9
]}

Hamaguchi Y. ^{[10
]}

Ishiyama A. ^{[11
]}

Shimada H. ^{[12
]}

机构：

[1] Department of General Surgery, Yokohama City University, Medical Center, Minami-ku, Yokohama 232-0024, 4-57, Urafunecho

[2] Department of Surgery, Yokohama Minami Kyosai Hospital, Yokohama City University

[3] Department of Surgery, Breast and Thyroid Division, Kanagawa Cancer Center

[4] Department of Surgery, Hiratsuka Kyosai Hospital, Yokohama City University

[5] Department of Surgery, St. Marianna University, School of Medicine

[6] Department of Surgery, School of Medicine, Tokai University

[7] Department of Surgery, School of Medicine, Kitasato University

[8] Department of Breast Surgery, Kameda Medical Center, Yokohama City University

[9] Department of Surgery, Saiseikai Yokohama City Nanbu Hospital, Yokohama City University

[10] Department of Surgery, Yokosuka Kyosai Hospital, Yokohama City University

[11] Department of Surgery, Yokohama Municipal Citizen's Hospital, Yokohama City University

[12] Department of Gastroenterological Surgery, Yokohama City University, Graduate School of Medicine

来源：

Breast Cancer | 2004年 / 11卷 / 4期

关键词：

Advanced breast cancer; Docetaxel; First-line chemotherapy;

D O I：

10.1007/BF02968045

中图分类号：

学科分类号：

摘要：

Purpose: Docetaxel is an active agent as first-line chemotherapy in patients with advanced breast cancer at a dosage of 100 mg/m 2. However, the efficacy of this agent as a first-line drug when used at a lower dosage is unclear. This study was performed to evaluate the clinical efficacy and safety of 60 mg/m 2 docetaxel for the treatment of breast cancer. Patients and Methods: This study enrolled 23 patients with advanced and/or metastatic breast cancer, who had not been treated with an anthracycline or taxane previously. Treatment with docetaxel was continued in patients showing a response until there was evidence of disease progression or unacceptable toxicity. Results: Among 20 fully evaluated patients, the overall response rate was 50.0% and the median time to progression was 31 weeks. The most commonly observed adverse events were neutropenia (78.2%) and fatigue (60.9%). Fluid retention occurred in only 8.7% of the patients. Adverse events did not cause discontinuation of the treatment. Conclusion: Docetaxel achieved good disease control with mild adverse events in first-line treatment at a dosage of 60 mg/m 2.

引用

页码：374 / 379

页数：5

共 18 条

[1] Aapro M.S., Combining new agents with anthracyclines in metastatic breast cancer: An overview of recent findings, Seminars in Oncology, 26, 1 SUPPL. 3, pp. 17-21, (1999)
[2] A'Hern R.P., Smith I.E., Ebbs S.R., Chemotherapy and survival in advanced breast cancer: The inclusion of doxorubicin in Cooper type regimens, British Journal of Cancer, 67, 4, pp. 801-805, (1993)
[3] Polychemotherapy for early breast cancer: An overview of the randomised trials, Lancet, 352, pp. 930-942, (1998)
[4] Crown J., A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer, Seminars in Oncology, 26, 1 SUPPL. 3, pp. 5-9, (1999)
[5] Ravdin P.M., Burris III H.A., Cook G., Eisenberg P., Kane M., Bierman W.A., Mortimer J., Genevois E., Bellet R.E., Phase II trial of docetaxel in advanced anthracyclineresistant or anthracenedione-resistant breast cancer, J Clin Oncol, 13, pp. 2879-2885, (1995)
[6] Valero V., Holmes F.A., Walters R.S., Theriault R.L., Esparza L., Fraschini G., Fonseca G.A., Bellet R.E., Buzdar A.U., Hortobagyi G.N., Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer, J Clin Oncol, 13, pp. 2886-2894, (1995)
[7] Sjostrom J., Mourisden H., Pluzanska A., Ottosson L., Bengtsson N.-O., Ostenstad B., Taxotere (T) versus methotrexate-5-fluorouracil (MF) in patients with advanced anthracycline-resistant breast cancer: Preliminary results of a randomized phase III study by Scandinavian breast cancer group, Proc Am Soc Clin Oncol, 17, 427, (1998)
[8] Bonneterre J., Roche H., Monnier A., Guastalla J.P., Namer M., Fargeot P., Assadourian S., Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure, British Journal of Cancer, 87, 11, pp. 1210-1215, (2002)
[9] Nabholtz J.-M., Senn H.J., Bezwoda W.R., Melnychuk D., Deschenes L., Douma J., Vandenberg T.A., Rapoport B., Rosso R., Trillet-Lenoir V., Drbal J., Molino A., Nortier J.W.R., Richel D.J., Nagykalnai T., Siedlecki P., Wilking N., Genot J.Y., Hupperets P.S.G.J., Pannuti F., Skarlos D., Tomiak E.M., Murawsky M., Alakl M., Riva A., Aapro M., Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracyclin
[10] Chan S., Friedrichs K., Noel D., Pinter T., Van Belle S., Vorobiof D., Duarte R., Gil M.G., Bodrogi I., Murray E., Yelle L., Von Minckwitz G., Korec S., Simmonds P., Buzzi F., Gonzalez Mancha R., Richardson G., Walpole E., Ronzoni M., Murawsky M., Alakl M., Riva A., Crown J., Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer, Journal of Clinical Oncology, 17, 8, pp. 2341-2354, (1999)

← 1 2 →